Pneumococcal conjugate vaccines and old adults

肺炎球菌结合疫苗和老年人

• 批准号: 7074454
• 负责人: Moon H. Nahm
• 金额: $ 31.75万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-15 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7074454
• 关键词: antibody; clinical research; serum

DESCRIPTION (provided by applicant): Pneumococcus is a major pathogen for older adults. Pneumococcal polysaccharide vaccine (PPV23) is not as effective in old adults (>65 years old) as it is in young adults, perhaps because PPV23 induces ineffective antibodies in old adults. We have recently examined antibodies elicited by the 7- and 9-valent pneumococcal conjugate vaccines (PCVs) in old adults and found them to be significantly more effective (opsonic) than the antibodies elicited with PPV23. Our working hypothesis is that, lgG2 antibodies elicited by PCVs in old adults have a higher avidity and therefore more functional capacity than the antibodies elicited by PPV23. To extend our observation and to evaluate this hypothesis, we propose to: 1) Extend our basic observation 1a) by determining the opsonic capacities for the remaining serotypes, by measuring opsonic capacity for one serotype with completely human reagents, and by measuring the capacity of the immune sera to protect mice against pneumococcal infections; 1b) by analyzing the sera from a previous study of 5-valent PCV to determine the opsonic capacities and antibody levels; and 1c) by determining the opsonic capacities of sera from young adults immunized with PPV23 for comparison. 2) Show that PCV- induced lgG2 anti-capsular polysaccharide antibodies are more effective and have a higher avidity than PPV23-induced antibodies by investigating 2a) the presence of antibodies to non-capsulated pneumococci, which may increase opsonic capability; 2b) the presence of non-lgG2 anti-capsule antibodies; 2c) the capacity of lgG2 anti-capsular PS antibodies to 6B, 14, and 23F capsular PS to opsonize in vitro using the sera from old adults immunized with PPV23 or PCVs; and 2d) the avidity of lgG2 anti-capsule antibodies. 3) Evaluate the structural basis for high avidity by determining 3a) the fraction of dimeric lgG2 anti-capsule antibodies and 3b) the structural differences in the V region of lgG2 antibodies using sera from young or old adults immunized with PPV23 or PCVs. Our long-term research interests have been to study pneumococcal antibody structure and its function. As a result, we have the reagents and techniques essential for this study and are uniquely prepared for this study. This study will enhance the knowledge of pneumococcal antibodies made by old adults and will help us determine if PCVs can be useful in pneumococcal vaccination of old adults, a major goal of our national health care policy.

描述（由申请人提供）：肺炎球菌是老年人的主要病原体。肺炎球菌多糖疫苗（PPV 23）在老年人（>65岁）中不如在年轻人中有效，可能是因为PPV 23在老年人中诱导无效抗体。我们最近检查了7价和9价肺炎球菌结合疫苗（PCV）在老年人中引起的抗体，发现它们比PPV 23引起的抗体显著更有效（调理剂）。我们的工作假设是，PCV在老年人中引发的IgG 2抗体具有更高的亲合力，因此比PPV 23引发的抗体具有更大的功能能力。为了扩展我们的观察和评估这一假设，我们建议：1）通过测定其余血清型的调理能力，通过用完全人试剂测量一种血清型的调理能力，以及通过测量免疫血清保护小鼠免受肺炎球菌感染的能力，来扩展我们的基本观察1a）; 1b）通过分析来自5价PCV的先前研究的血清以确定调理能力和抗体水平;和1c）通过确定来自用PPV 23免疫的年轻成人的血清的调理能力以进行比较。2)通过研究2a）可能增加调理能力的非包囊化肺炎球菌抗体的存在; 2b）非IgG 2抗包囊抗体的存在; 2c）IgG 2抗荚膜PS抗体对6 B、14和23 F荚膜PS在体外使用来自用PPV 23或PCV免疫的老年人的血清调理的能力;和3)通过测定3a）二聚体IgG 2抗荚膜抗体的分数和3b）IgG 2抗体V区的结构差异（使用PPV 23或PCV免疫的年轻或老年成人血清），评价高亲合力的结构基础。我们的长期研究兴趣是研究肺炎球菌抗体的结构及其功能。因此，我们拥有本研究所需的试剂和技术，并为本研究进行了独特的准备。这项研究将提高老年人肺炎球菌抗体的知识，并将帮助我们确定PCV是否可用于老年人肺炎球菌疫苗接种，这是我们国家卫生保健政策的主要目标。